glp-1 effect on cholesterol The cardiovascular effects of receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action Cardiovascular Protection with a Long-Acting

Frias JP, Nauck MA, Van J et al (2018) Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

31 In the fasted state, PYY 1-36 predominates in the circulation, whereas post-prandially, PYY 3-36 is the major circulating form

IL-33-responsive lineage- CD25 + CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs

The evidence here is actually decent, though the effects are modest

Conclusions Although it is well recognized that Cav-1 is involved in all the steps that regulate GLP-1 function, these aspects are not fully elucidated